MediciNova shares are trading lower after the company announced the topline results from MN-001-NATG-202, a Phase 2 clinical trial evaluating MN-001 for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease associated with type 2 diabetes mellitus.